We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Leukocyte Depletion of Autologous Whole Blood (LDAWB-2001)

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00176124
First Posted: September 15, 2005
Last Update Posted: June 10, 2008
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
Philipps University Marburg Medical Center
Information provided by:
Heidelberg University
  Purpose
Leukocyte depletion of autologous whole blood prior to storage does not reduce infection rate (wound, urinary tract, other), use of antibiotic treatment and length of hospital stay but may increase retransfusion perioperatively during hip arthroplasty and allogenic transfusion rate

Condition Intervention Phase
Infection Bacterial Infection Sepsis Procedure: leukocyte depletion of whole blood Other: Leukocyte filtration/Depletion Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Leukocyte Depletion of Autologous Whole Blood: Impact on Perioperative Infection Rate and Length of Hospital Stay for Hip Arthroplasty Patients

Resource links provided by NLM:


Further study details as provided by Heidelberg University:

Primary Outcome Measures:
  • Comparison of infection rate (wound, urinary tract, other), use of antibiotic treatment and length of hospital stay [ Time Frame: 90 days ]

Secondary Outcome Measures:
  • Blood loss and transfusion rate [ Time Frame: 90 days ]

Enrollment: 1089
Study Start Date: April 2001
Study Completion Date: September 2005
Primary Completion Date: April 2005 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
No Intervention: 1
storage and transfusion of autologous whole blood without leukocyte depletion : Control group
Procedure: leukocyte depletion of whole blood
Experimental: 2
storage and transfusion of leukocyte depleted autologous whole blood : leukocyte depletion group
Procedure: leukocyte depletion of whole blood Other: Leukocyte filtration/Depletion
leukocyte depletion filters as used routinely: filters (prestorage) inherent to the blood bag sets by gravity force following storage on cold plate for 2 hours
Other Name: Fresenius leukocyte depletion whole blood filters

  Show Detailed Description

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 85 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • • ASA I-III,

    • Age 18-85 years,
    • Body weight 50-125 kg
    • If female, with either a history of an accepted method of anticonception for at least 3 month prior and 1 month following the termination of the study or climacteric or with a negative betA- HCG-Test in urine or serum.
    • Preoperative blood donation of at least 2 units (450mL whole blood)
    • Preoperative hemoglobin level > 10 mg/dL
    • Able and willing to sign informed consent

Exclusion Criteria:

  • Subjects with a contraindication for preoperative blood donation (PAD) (in 12, PP 36-43).

    • systemic infection
    • acute bacterial or viral diseases
    • anemia (Hb > 11g/dL)
    • myocardial infarction within the past 6 month,
    • instable angina pectoris
    • vascular stenosis (i.e. of the coronary or internal carotid arteries)
    • hemodynamic relevant valvular stenosis
    • heart failure > NYHA II
    • history of strokes or TIA
    • steroid therapy,
    • immune deficiency,
    • hematological or endocrinological disease,
    • coagulopathy,
    • history of organ transplantation,
    • simultaneous participation in a second study
    • pregnancy
    • membership at Jehovah's Witnesses
    • intended use of a cell saver
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00176124


Locations
Germany
Clinic of Anesthesiology and Critical Care Medicine, Faculty of Clinical Medicine MAnnheim, University of Heidelberg, Germany
Mannheim, Baden-Wuerttemberg, Germany, 68167
Klinikum Garmisch Partenkirchen
Garmisch Partenkirchen, Bavaria, Germany, 82467
Institute of Transfusion Medicine and Hemostasiology, University of MArburg
Marburg, Germany, 35043
Sponsors and Collaborators
Heidelberg University
Philipps University Marburg Medical Center
Investigators
Study Chair: Thomas Frietsch, MD, PhD Clinic of Anesthesiology and Critical Care Medicine, Faculty of Clinical Medicine Mannheim, University of Heidelberg
  More Information

Additional Information:
Publications:
Responsible Party: Thomas Frietsch, MD PhD, University of Heidelberg
ClinicalTrials.gov Identifier: NCT00176124     History of Changes
Other Study ID Numbers: UniKlinMa-TF-2001-1
ISRCTN 99578441
First Submitted: September 11, 2005
First Posted: September 15, 2005
Last Update Posted: June 10, 2008
Last Verified: June 2008

Keywords provided by Heidelberg University:
leukocyte depletion, autologous transfusion,
infection
bacterial infection
sepsis, antibiotics

Additional relevant MeSH terms:
Infection
Communicable Diseases
Sepsis
Bacterial Infections
Systemic Inflammatory Response Syndrome
Inflammation
Pathologic Processes


To Top